AR100204A1 - Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye - Google Patents

Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye

Info

Publication number
AR100204A1
AR100204A1 ARP150101262A ARP150101262A AR100204A1 AR 100204 A1 AR100204 A1 AR 100204A1 AR P150101262 A ARP150101262 A AR P150101262A AR P150101262 A ARP150101262 A AR P150101262A AR 100204 A1 AR100204 A1 AR 100204A1
Authority
AR
Argentina
Prior art keywords
adipoilbis
pirrolidina
carboxilato
composite
parts
Prior art date
Application number
ARP150101262A
Other languages
English (en)
Inventor
Denis Alexis
Mirguet Olivier
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of AR100204A1 publication Critical patent/AR100204A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Reivindicación 1: Un compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato) caracterizado porque es 1,1-adipoilbis(pirrolidina-2-carboxilato) de (2R,2R)-bis(((((tetrahidro-2H-piran-4-il)oxi)carbonil)oxi)metilo) según la fórmula (1). Reivindicación 2: El compuesto según la reivindicación 1, caracterizado porque está en forma cristalina.
ARP150101262A 2014-04-29 2015-04-27 Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye AR100204A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1407506.3A GB201407506D0 (en) 2014-04-29 2014-04-29 Novel compound

Publications (1)

Publication Number Publication Date
AR100204A1 true AR100204A1 (es) 2016-09-21

Family

ID=50972033

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150101262A AR100204A1 (es) 2014-04-29 2015-04-27 Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye

Country Status (26)

Country Link
US (3) US9701668B2 (es)
EP (1) EP3137457B1 (es)
JP (1) JP6445046B2 (es)
KR (1) KR20160145617A (es)
CN (1) CN106459016B (es)
AR (1) AR100204A1 (es)
AU (1) AU2015252184B2 (es)
BR (1) BR112016025129A2 (es)
CA (1) CA2947060C (es)
CL (1) CL2016002721A1 (es)
CR (1) CR20160508A (es)
DO (1) DOP2016000292A (es)
EA (1) EA032129B1 (es)
ES (1) ES2731253T3 (es)
GB (1) GB201407506D0 (es)
IL (2) IL248249A0 (es)
MA (1) MA39406B1 (es)
MX (1) MX2016014246A (es)
MY (1) MY191088A (es)
PE (1) PE20161558A1 (es)
PH (1) PH12016502006A1 (es)
SG (1) SG11201608371RA (es)
TW (1) TWI676624B (es)
UA (1) UA119871C2 (es)
UY (1) UY36098A (es)
WO (1) WO2015165833A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline
GB201518950D0 (en) 2015-10-27 2015-12-09 Glaxosmithkline Ip Dev Ltd Compound
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0915088T3 (da) 1997-10-31 2003-01-27 Hoffmann La Roche D-prolinderivater
US6903129B2 (en) * 2001-12-14 2005-06-07 Hoffman-La Roche Inc. D-proline prodrugs
WO2004108733A1 (en) 2003-06-05 2004-12-16 Pfizer Products Inc. Beta-lactamase inhibitor prodrug
GB0313386D0 (en) 2003-06-10 2003-07-16 Univ London Treatment of disease
CA2604206A1 (en) 2005-04-12 2006-10-19 Meiji Seika Kaisha, Ltd. 2-thioethenyl substituted carbapenem derivatives
GB0712503D0 (en) 2007-06-27 2007-08-08 Therapeutics Pentraxin Ltd Use
UA108227C2 (xx) 2010-03-03 2015-04-10 Антигензв'язуючий білок
US9737505B2 (en) 2014-04-29 2017-08-22 Glaxosmithkline Intellectual Property Development Limited Prodrug of 1,1′-(1,6-dioxo-1,6-hexanediyl)bis-D-proline

Also Published As

Publication number Publication date
EP3137457B1 (en) 2019-04-17
JP2017514829A (ja) 2017-06-08
UA119871C2 (uk) 2019-08-27
BR112016025129A2 (pt) 2017-08-15
IL248249A0 (en) 2016-11-30
US20180099955A1 (en) 2018-04-12
PE20161558A1 (es) 2017-01-06
CA2947060A1 (en) 2015-11-05
US9873686B2 (en) 2018-01-23
EA032129B1 (ru) 2019-04-30
MA39406B1 (fr) 2018-04-30
US9701668B2 (en) 2017-07-11
CN106459016B (zh) 2019-11-01
TWI676624B (zh) 2019-11-11
MA39406A1 (fr) 2017-07-31
SG11201608371RA (en) 2016-11-29
GB201407506D0 (en) 2014-06-11
EP3137457A1 (en) 2017-03-08
JP6445046B2 (ja) 2018-12-26
AU2015252184A1 (en) 2016-10-27
US10597385B2 (en) 2020-03-24
MY191088A (en) 2022-05-30
MX2016014246A (es) 2017-02-06
IL279120A (en) 2021-01-31
AU2015252184B2 (en) 2017-11-02
CN106459016A (zh) 2017-02-22
WO2015165833A1 (en) 2015-11-05
CA2947060C (en) 2023-09-26
DOP2016000292A (es) 2017-11-15
UY36098A (es) 2015-11-30
TW201625598A (zh) 2016-07-16
KR20160145617A (ko) 2016-12-20
PH12016502006B1 (en) 2016-12-19
CL2016002721A1 (es) 2017-01-20
US20160075694A1 (en) 2016-03-17
EA201692185A1 (ru) 2017-06-30
PH12016502006A1 (en) 2016-12-19
CR20160508A (es) 2017-03-10
ES2731253T3 (es) 2019-11-14
US20170267665A1 (en) 2017-09-21

Similar Documents

Publication Publication Date Title
DOP2019000005A (es) 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2
MX2020011104A (es) Composiciones farmaceuticas de compuestos terapeuticamente activos y sus metodos de uso.
CR20210079A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
CR20160069A (es) Compuestos terapéuticamente activos y sus métodos de uso
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
CL2015002164A1 (es) Formulación combinada de dos compuesos antivirales.
CR20160272A (es) REGULADORES DE Nrf2
MX2016016993A (es) Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo.
MX2015012644A (es) Tratamiento de cataplejia.
CR20150440A (es) Nuevos derivados de piridina
MX2018003700A (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de higado graso, y uso de los mismos.
GT201500247A (es) Imidazopiridazinas sustituidas
CR20150204A (es) Nuevos derivados de piridina
MX2017007377A (es) Compuestos organicos.
UY35276A (es) Nuevos compuestos que inhiben la actividad de Lp-PLA2
CL2018001493A1 (es) Nuevos derivados de fenilo
CR20160448A (es) Nuevos derivados de piridina
CR20160459A (es) Nuevos derivados de piridina
MX2017009849A (es) Composiciones de profármaco de monometilfumarato.
MX386008B (es) Compuestos citotóxicos y antimitóticos, y métodos para utilizarlos.
CR20150511A (es) Nuevos derivados de purina
CL2017001100A1 (es) Nuevas triazolo[4,5-d]pirimidinas
EA201690621A1 (ru) Полиэтиленгликольсодержащие композиции
AR100204A1 (es) Compuesto de 1,1-adipoilbis(pirrolidina-2-carboxilato), composición farmacéutica que lo comprende y conjunto de partes que los incluye
BR112017024126A2 (pt) composições farmacêuticas e uso das mesmas

Legal Events

Date Code Title Description
FG Grant, registration